Cargando…

Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331

Detalles Bibliográficos
Autores principales:	Abdul-Ghani, Muhammad, Migahid, Osama, Megahed, Ayman, Adams, John, Triplitt, Curtis, DeFronzo, Ralph A., Zirie, Mahmoud, Jayyousi, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2017
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521968/ https://www.ncbi.nlm.nih.gov/pubmed/28615237 http://dx.doi.org/10.2337/dc17-er08d

Ejemplares similares

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
por: Ponirakis, Georgios, et al.
Publicado: (2020)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
por: DeFronzo, Ralph A., et al.
Publicado: (2010)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population
por: Iskandar, Saadallah, et al.
Publicado: (2019)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
por: Ponirakis, Georgios, et al.
Publicado: (2021)

Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
por: Ponirakis, Georgios, et al.
Publicado: (2021)

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients
por: Freire, Paula Vieira, et al.
Publicado: (2015)

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
por: Clarke, Geoffrey D., et al.
Publicado: (2017)

Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study
por: López-Cano, Carolina, et al.
Publicado: (2022)

Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice
por: Iizuka, Yuzuru, et al.
Publicado: (2018)

The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
por: Vaccaro, Olga, et al.
Publicado: (2012)

Effects of Exercise, Metformin, Pioglitazone and Exenatide Treatment on Inflammation Induced Insulin Resistance and Ubiquitin Proteasome System in Diabetes and Obesity
por: Akarsu, Ersin, et al.
Publicado: (2021)

Effect of intravenous dexmedetomidine administered as bolus or as bolus-plus-infusion on subarachnoid anesthesia with hyperbaric bupivacaine
por: Kavya, Upadhya R, et al.
Publicado: (2018)

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study
por: Solis-Herrera, Carolina, et al.
Publicado: (2013)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Examination of Jeltrate®Plus as a tissue equivalent bolus material
por: Babic, Steven, et al.
Publicado: (2002)

Sodium‐glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials
por: Liao, Hung‐Wei, et al.
Publicado: (2018)

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
por: Wang, Fei, et al.
Publicado: (2017)

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
por: Gaebler, Julia A, et al.
Publicado: (2012)

The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans
por: Palavicini, Juan P., et al.
Publicado: (2021)

Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418
por: Solomon, Sharon D., et al.
Publicado: (2017)

Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418
por: Solomon, Sharon D., et al.
Publicado: (2017)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance
por: Espinoza, Sara E., et al.
Publicado: (2016)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients
por: Barakat, Lolwa, et al.
Publicado: (2013)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)

Correction to: Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t8h8b8upc1srbp9plni8b5p43q